evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

2,543 questions · 2,589 findings · 168 reviews · Schizophrenia

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 601 · 23.2%GRADE not reported 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day)

Global state: no improvement ‐ short term · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes global state: no improvement ‐ short term compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).

1 finding from 1 review

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs HIGH DOSE (> 800 mg/day ‐ all medium term)

Behaviour: deterioration of behaviour (categorised as reason to leave early) · schizophrenia

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) may leads to higher behaviour: deterioration of behaviour (categorised as reason to… compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (low certainty).

1 finding from 1 review

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs HIGH DOSE (> 800 mg/day ‐ all medium term)

Adverse effects: unspecified extrapyramidal symptoms · schizophrenia

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: unspecified extrapyramidal symptoms compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).

1 finding from 1 review

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day)

Global state: needing additional medication (sedation with chloral hydrate or a barbiturate > 5 times) ‐ medium term · patients with schizophrenia

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) showed no clear difference in global state: needing additional medication (sedation with chloral… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (low certainty).

1 finding from 1 review

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day)

Behaviour: agitation and restlessness ‐ medium term (categorised as adverse event) · patients with schizophrenia

It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes behaviour: agitation and restlessness ‐ medium term (categorised as… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).

1 finding from 1 review

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs MEDIUM DOSE (401 mg/day to 800 mg/day)

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: extrapyramidal symptoms (unspecified extrapyramidal… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).

1 finding from 1 review

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) vs HIGH DOSE (> 800 mg/day ‐ all medium term)

Global state: No clinically significant response (as defined by the original studies) · schizophrenia

CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to higher global state: no clinically important improvement ‐ medium term compared with HIGH DOSE (> 800 mg/day ‐ all medium term) (moderate certainty).

1 finding from 1 review

INTENSIVE CASE MANAGEMENT vs NON‐INTENSIVE CASE MANAGEMENT

Social functioning 2. Employment status ‐ by medium term ‐ spent > 1 day employed · people with severe mental disorders

It is very uncertain whether intensive Case Management changes social functioning 2. Employment status ‐ by medium term ‐ spent > 1… compared with non‐Intensive Case Management (very low certainty).

1 finding from 1 review